| Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study |
67 |
| Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study |
50 |
| Global, regional, and national incidence, prevalence, and mortality of HIV, 1980- and forecasts to for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017 |
47 |
| Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting |
43 |
| Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study |
38 |
| Community-level changes in condom use and uptake of HIV pre-exposure prophylaxis by gay and bisexual men in Melbourne and Sydney, Australia: results of repeated behavioural surveillance in 2013-17 |
37 |
| Universal test and treat and the HIV epidemic in rural South Africa: a phase open-label, community cluster randomised trial |
33 |
| Reliability of HIV rapid diagnostic tests for self-testing compared with testing by health-care workers: a systematic review and meta-analysis |
24 |
| Barriers and strategies to achieve a cure for HIV |
24 |
| Association of antiretroviral therapy with high-risk human papillomavirus, cervical intraepithelial neoplasia, and invasive cervical cancer in women living with HIV: a systematic review and meta-analysis |
22 |
| Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase non-inferiority trial |
21 |
| Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study |
21 |
| Community based distribution of oral HIV self-testing kits in Zambia: a cluster-randomised trial nested in four HPTN 071 (PopART) intervention communities |
20 |
| Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial |
20 |
| Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study |
19 |
| Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase randomised, non-inferiority trial |
19 |
| Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1:48 week results of a randomised, open-label, multicentre, phase non-inferiority trial |
19 |
| Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase non-inferiority trial |
19 |
| Epidemiology and prevention of sexually transmitted infections in men who have sex with men at risk of HIV |
19 |
| Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: a collaboration of cohort studies |
18 |
| Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase non-inferiority trial |
18 |
| Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase randomised, double-blind, placebo-controlled trial |
17 |
| Dynamics of the HIV outbreak and response in Scott County, IN, USA, 2011-15: a modelling study |
17 |
| Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial |
17 |
| HIV prevention cascades: a unifying framework to replicate the successes of treatment cascades |
17 |
| Global PrEP roll-out: recommendations for programmatic success |
16 |
| Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase non-inferiority trial |
15 |
| Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research |
15 |
| The cascade of HIV care among key populations in Indonesia: a prospective cohort study |
15 |
| Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1:100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies |
15 |
| Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial |
14 |
| Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial |
14 |
| Migration and risk of HIV acquisition in Rakai, Uganda: a population-based cohort study |
14 |
| Sexual behaviour and incidence of HIV and sexually transmitted infections among men who have sex with men using daily and event-driven pre-exposure prophylaxis in AMPrEP: 2 year results from a demonstration study |
14 |
| Targeted combination prevention to support female sex workers in Zimbabwe accessing and adhering to antiretrovirals for treatment and prevention of HIV (SAPPH-IRe): a cluster-randomised trial |
13 |
| Incidence of first and second primary cancers diagnosed among people with HIV, 1985-2013: a population-based, registry linkage study |
13 |
| Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial |
13 |
| The global Optima HIV allocative efficiency model: targeting resources in efforts to end AIDS |
13 |
| The disconnect between individual-level and population-level Goatee. HIV prevention benefits of antiretroviral treatment |
13 |
| Strategies for engaging men in HIV services |
12 |
| Does U=U for breastfeeding mothers and infants? Breastfeeding by mothers on effective treatment for HIV infection in high-income settings |
12 |
| Community-based HIV prevalence in KwaZulu-Natal, South Africa: results of a cross-sectional household survey |
11 |
| HIV treatment in pregnancy |
11 |
| Detection and treatment of Fiebig stage I HIV-1 infection in young at-risk women in South Africa: a prospective cohort study |
11 |
| Sensitivity and specificity of WHO's recommended four-symptom screening rule for tuberculosis in people living with HIV: a systematic review and meta-analysis |
11 |
| Re-emergence of HIV related to injecting drug use despite a comprehensive harm reduction environment: a cross-sectional analysis |
11 |
| HIV drug resistance in low-income and middle-income countries |
11 |
| Efficacy and safety of varenicline for smoking cessation in people living with HIV in France (ANRS 144 Inter-ACTIV): a randomised controlled phase 3 clinical trial |
11 |
| Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study |
11 |
| Pre-exposure prophylaxis 2.0: new drugs and technologies in the pipeline |
11 |
